Histone deacetylase inhibitor panobinostat benefits the therapeutic efficacy of oncolytic herpes simplex virus combined with pd-1/pd-l1 blocking in glioma and squamous cell carcinoma models

HIGHLIGHTS

• who: Yinglin Wu and colleagues from the Department of Immunology, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China have published the research work: Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models, in the Journal: Viruses 2022, 2796 of 15/Dec/2022
• what: In this study oncolytic activity in vitro and antitumor therapeutic efficacy in vivo when with oHSV and panobinostat were investigated. In this study, only a subcutaneous tumor model was studied, considering that . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.